Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZeTA: Zanubrutinib and Tislelizumab in Post-CAR-T Large B-Cell Lymphoma
NCT06167785Phase 2Recruiting
- Sponsor
- University Health Network
- Start
- Jun 2025
- Primary completion
- Apr 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, tislelizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by University Health Network. Started Jun 2025; status: recruiting.
02
Drugs
zanubrutinibtislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06167785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167785.